Antibiotic combination therapy for steroid Withdrawal in steroid-dependent ulcerative colitis

Digestion

Volumn 83, Issue 3, 2011, Pages 198-203

  Terao, Shuichi ^a   Yamashiro, Kenzo ^a   Tamura, Isamu ^a   Hirano, Takahiro ^a   Ohkusa, Toshifumi ^b   Kato, Kimitoshi ^c  

^a Shinko Kakogawa Hospital   (Japan)

^b JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c NIHON UNIVERSITY   (Japan)

Author keywords

Antibiotic combination therapy; Steroid dependent patients; Ulcerative colitis

Indexed keywords

AMOXICILLIN; AZATHIOPRINE; METRONIDAZOLE; PREDNISONE; STEROID; TETRACYCLINE;

ANTIBIOTIC COMBINATION THERAPY; ANTIBIOTIC THERAPY; CLINICAL ARTICLE; CLINICAL EXAMINATION; CONFERENCE PAPER; DIARRHEA; ENDOSCOPY; FEVER; FOLLOW UP; HEADACHE; HISTOPATHOLOGY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER DYSFUNCTION; MAINTENANCE THERAPY; NAUSEA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RASH; REMISSION; STEROID THERAPY; STOMACH BIOPSY; TREATMENT DURATION; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; ULCERATIVE COLITIS;

ADOLESCENT; ADULT; AGED; AMOXICILLIN; ANTI-BACTERIAL AGENTS; AZATHIOPRINE; COLITIS, ULCERATIVE; DRUG THERAPY, COMBINATION; FEMALE; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; METRONIDAZOLE; MIDDLE AGED; REMISSION INDUCTION; TETRACYCLINE; YOUNG ADULT;

EID: 79251571446     PISSN: 00122823     EISSN: None     Source Type: Journal    
DOI: 10.1159/000321811     Document Type: Conference Paper

References (27)

1. Carter MJ, Lobo AJ, Travis SPL, et al: Guidelines for the management of inflammatory bowel disease in adults. Gut 2004; 53(suppl 5):V1-V16.
2. Faubion WA Jr, Loftus EV Jr, Harmsen WS, Zinsmeister AR, Sandborn WJ: The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 2001; 121: 255-260.
3. Irving PM, Gearry RB, Sparrow MP, Gibson PR: Appropriate use of corticosteroids in Crohn's disease. Aliment Pharmacol Ther 2007; 26: 313-329.
4. Lichtenstein GR, Sbreu MT, Cohen R, Tremaine W: American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterolog y 2006; 130: 940-987. (Pubitemid 43374543)
5. Actis GC, Fadda M, Pellicano R, David E, Rizzetto M, Sapino A: The 17-year single-center experience with the use of azathio-prine to maintain remission in ulcerative colitis. Biomed Pharmacother 2009; 63: 362-365.
6. Ohkusa T, Kato K, Terao S, Chiba T, Mabe K, Murakami K, Mizokami Y, Sugiyama T, Yanaka A, Takeuchi Y, Yamato S, Yokoyama T, Okayasu I, Watanabe S, Tajiri H, Sato N: Newly developed antibiotic combination therapy for ulcerative colitis: a double-blind placebo-controlled multicenter trial. Am J Gastroenterol 2010; 105:1820-1829.
7. Lichtiger S, Present DH, Kornbluth A, Gelernt I, Bauer J, Galler G, Michelassi F, Hanauer S: Cyclosporine in severe ulcerative colitis refractory to steroid therapy volume. N Engl J Med 1994; 330:1841-1845.
8. Matts SG: The value of rectal biopsy in the diagnosis of ulcerative colitis. Q J Med 1961; 30:393-407.
9. Ardizzone S, Maconi G, Russo A, Imbesi V, Colombo E, Bianchi Porro G: Randomised controlled trial of azathioprine and 5-ami-nosalicylic acid for treatment of steroid-dependent ulcerative colitis. Gut 2006; 55: 1525-1526.
10. Beaugerie L, Brousse N, Bouvier AM, Colombel JF, Lémann M, Cosnes J, Hébuterne X, Cortot A, Bouhnik Y, Gendre JP, Simon T, Maynadié M, Hermine O, Faivre J, Carrat F, CESAME Study Group: Lymphoproliferative disorders in patients receiving thiopu-rines for inflammatory bowel disease: a prospective observational cohort study. Lancet 2009; 374: 1617-1625.
11. Baumgart DC, Pintoffl JP, Sturm A, Wiedenmann B, Dignass AU: Tacrolimus is safe and effective in patients with severe steroid-refractory or steroid-dependent inflammatory bowel disease - a long-term follow-up. Am J Gastroenterol 2006; 101:1048-1056.
12. Armuzzi A, De Pascalis B, Lupascu A, Fedeli P, Leo D, Mentella MC, Vincenti F, Melina D, Gasbarrini G, Pola P, Gasbarrini A: Infliximab in the treatment of steroid-dependent ulcerative colitis. Eur Rev Med Pharmacol Sci 2004; 8: 231-233.
13. Bultman E, Kuipers EJ, van der Woude CJ: Systematic review: steroid withdrawal in an-ti-TNF-treated patients with inflammatory bowel disease. Aliment Pharmacol Ther 2010; 32:313-323.
14. Ljung T, Thomsen OØ;, Vatn M, Karlén P, Karlsen LN, Tysk C, Nilsson SU, Kilander A, Gillberg R, Grip O, Lindgren S, Befrits R, Löfberg R: Granulocyte, monocyte/macro-phage apheresis for inflammatory bowel disease: the first 100 patients treated in Scandinavia. Scand J Gastroenterol 2007; 42:221-227.
15. Domènech E, Hinojosa J, Esteve-Comas M, Gomollón F, Herrera JM, Bastida G, Obrador A, Ruiz R, Saro C, Gassull MA, Spanish Group for the Study of Crohn's Disease and Ulcerative Colitis (GETECCU): Granulocyte aphaeresis in steroid-dependent inflammatory bowel disease: a prospective, open, pilot study. Aliment Pharmacol Ther 2004; 20:1347-1352.
16. Sands BE, Sandborn WJ, Feagan B, Löfberg R, Hibi T, Wang T, Gustofson LM, Wong CJ, Vandervoort MK, Hanauer S, Adacolumn Study Group: A randomized, double-blind, sham-controlled study of granulocyte/monocyte apheresis for active ulcerative colitis. Gastroenterol 2008; 135:400-409.
17. Neish AS: Microbes in gastrointestinal health and disease. Gastroenterology 2009; 136: 65-80.
18. Porter CK, Tribble DR, Aliaga PA, Halvorson HA, Riddle MS: Infectious gastroenteritis and risk of developing inflammatory bowel disease. Gastroenterology 2008; 135:781-786.
19. Truelove SC, Jewell DP: Intensive intravenous regimen for severe attacks of ulcerative colitis. Lancet 1974; i: 1067-1070.
20. Dickinson RJ, O'Connor HJ, Pinder I, Hamilton I, Johnston D, Axon AT: Double-blind controlled trial of oral vancomycin as ad-junctive treatment in acute exacerbations of idiopathic colitis. Gut 1985; 26: 1380-1384.
21. Chapman RW, Selby WS, Jewell DP: Controlled trial of intravenous metronidazole as an adjunct to corticosteroids in severe ulcerative colitis. Gut 1986; 27:1210-1212.
22. Mantzaris GJ, Hatzis A, Kontogiannis P, Triadaphyllou G: Intravenous tobramycin and metronidazole as an adjunct to corticoste-roids in acute, severe ulcerative colitis. Am J Gastroenterol 1994; 89:43-46.
23. Turunen UM, Färkkilä MA, Hakala K, Seppälä K, Sivonen A, Ogren M, Vuoristo M, Valtonen V V, Miettinen TA: Long-term treatment of ulcerative colitis with cipro-floxacin: a prospective, double-blind, placebo-controlled study. Gastroenterology 1998; 115: 1072-1078.
24. Gionchetti P, Rizzello F, Ferrieri A, Venturi A, Brignola C, Ferretti M, Peruzzo S, Miglioli M, Campieri M: Rifaximin in patients with moderate or severe ulcerative colitis refractory to steroid-treatment: a double-blind, placebo-control led trial. Dig Dis Sci 1999; 44: 1220-1221.
25. Ohkusa T, Sato N, Ogihara T, Morita K, Ogawa M, Okayasu I: Fusobacterium varium localized in the colonic mucosa of patients with ulcerative colitis stimulates species-specific antibody. J Gastroenterol Hepatol 2002; 17:849-853.
26. Ohkusa T, Nomura T, Terai T, Miwa H, Kobayashi O, Hojo M, Takei Y, Ogihara T, Hirai S, Okayasu I, Sato N: Effectiveness of antibiotic combination therapy in patients with active ulcerative colitis: a randomized, controlled pilot trial with long-term follow-up. Scand J Gastroenterol 2005; 40:1334-1342.
27. Nomura T, Ohkusa T, Okayasu I, Yoshida T, Sakamoto M, Hayashi H, Benno Y, Hirai S, Hojo M, Kobayashi O, Terai T, Miwa H, Takei Y, Ogihara T, Sato N: Mucosaassociated bacteria in ulcerative colitis before and after antibiotic combination therapy. Aliment Pharmacol Ther 2005; 21:1017-1027.